Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a long-term partnership with UK-based Bio Immunitas, a firm built around a proprietary human Recombinant Protein Platform (hRPP). This strategic collaboration aims to accelerate Bio Immunitas’s manufacturing capabilities from the lab to clinic, including IND-enabling CMC services for two of the UK firm’s preclinical recombinant protein products. The financial details of the deal were not disclosed.
Partnership Details
GenScript ProBio will provide comprehensive support to Bio Immunitas to expedite the firm’s manufacturing process, from laboratory research to clinical trials. This includes IND-enabling CMC services for two of Bio Immunitas’s preclinical recombinant protein products, which are crucial for advancing these products towards clinical development.
Bio Immunitas: hRPP Program and Disease Targets
Bio Immunitas has applied its hRPP program to create potential antibody products targeting three key disease areas: anti-SARs-CoV-2, anti-inflammatory, and a first-in-class longevity/anti-aging antibody/immunotherapy designed to clear senescent cells. These innovative products have the potential to address significant unmet medical needs in the treatment and prevention of various diseases.
GenScript ProBio: Global CRO Affiliation
GenScript ProBio is affiliated with the global Contract Research Organization (CRO) GenScript Biotech Corporation. This affiliation provides GenScript ProBio with a robust network and resources to support the development and manufacturing needs of its partners, enhancing the efficiency and quality of biologics development.-Fineline Info & Tech
